Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Improving cure rates in NHL and future treatments

Paolo Caimi • 3 Jun 2021
EHA 2021
Lymphoma Non-Hodgkin Lymphoma Antibodies CAR-T Loncastuximab tesirine Polatuzumab vedotin Selinexor

Paolo Caimi, MD, University Hospitals Cleveland Medical Center & Case Western Reserve University, Cleveland, OH, talks on the improving cure rates of non-Hodgkin lymphoma (NHL) and discussess where he sees the field moving in the future. Dr Caimi also outlines novel therapies being developed for NHL treatment, including loncastuximab tesirine, polatuzumab, and selinexor, and comments on the need to target therapies more accurately. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Paolo Caimi

2:26
Feasibility of sequential treatment with CD19-targeted agents in patients with LBCL
Paolo Caimi • 11 Dec 2022
2:48
Correlation between ctDNA levels and outcomes in patients with NHL treated with CAR-T therapy
Paolo Caimi • 11 Dec 2022
3:35
Outcomes of patients with DLBCL who relapse early following R-ICE chemoimmunotherapy
Paolo Caimi • 11 Dec 2022
2:42
Siltuximab for first-line treatment of CRS in patients receiving CAR-T therapy
Paolo Caimi • 11 Dec 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals